Steward Partners Investment Advisory LLC Acquires 194 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Steward Partners Investment Advisory LLC boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 164.4% in the fourth quarter, HoldingsChannel reports. The firm owned 312 shares of the biotechnology company’s stock after purchasing an additional 194 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Sarepta Therapeutics were worth $38,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares in the last quarter. Summit Partners Public Asset Management LLC increased its holdings in Sarepta Therapeutics by 547.9% in the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Larson Financial Group LLC increased its holdings in Sarepta Therapeutics by 1,649.8% in the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Sarepta Therapeutics by 30.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 78,244 shares of the biotechnology company’s stock worth $9,772,000 after purchasing an additional 18,095 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in Sarepta Therapeutics by 19.1% in the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company’s stock worth $8,228,000 after purchasing an additional 10,815 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $73.54 on Wednesday. The company’s 50 day moving average is $110.18 and its 200-day moving average is $119.13. Sarepta Therapeutics, Inc. has a 12-month low of $73.06 and a 12-month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm has a market cap of $7.14 billion, a P/E ratio of 58.83 and a beta of 0.79.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Piper Sandler reduced their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday. Finally, Royal Bank of Canada reduced their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.23.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.